Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
34.07
-0.09 (-0.26%)
At close: May 22, 2026, 4:00 PM EDT
34.00
-0.07 (-0.20%)
After-hours: May 22, 2026, 7:00 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Teva Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $40.27. The average 1-year stock price forecast is 18.20% higher than the current stock price, while the lowest is $31 (-9.01%) and the highest is $50 (+46.76%).
Price Target: $40.27 (+18.20%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $38 → $40 | Buy | Maintains | $38 → $40 | +17.41% | May 6, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +17.41% | Apr 30, 2026 |
| UBS | UBS | Strong Buy Maintains $36 → $42 | Strong Buy | Maintains | $36 → $42 | +23.28% | Apr 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $41 → $42 | Buy | Reiterates | $41 → $42 | +23.28% | Apr 30, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | +32.08% | Apr 30, 2026 |
Financial Forecast
Revenue This Year
16.94B
from 17.26B
Decreased by -1.84%
Revenue Next Year
17.63B
from 16.94B
Increased by 4.07%
EPS This Year
2.41
from 1.21
Increased by 98.92%
EPS Next Year
3.18
from 2.41
Increased by 32.22%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.5B | 18.3B | |
| Avg | 16.9B | 17.6B | |
| Low | 16.2B | 16.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.6% | 7.7% | |
| Avg | -1.8% | 4.1% | |
| Low | -6.2% | -0.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.86 | 3.34 | |
| Avg | 2.41 | 3.18 | |
| Low | 1.99 | 3.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 136.0% | 38.7% | |
| Avg | 98.9% | 32.2% | |
| Low | 64.4% | 25.4% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.